The high-throughput nature of technologies like phage-display and single B-cell sequencing make it possible to identify hundreds to thousands of potentially high-affinity antibodies for development. Investigation of these hits requires expression of as full-length antibodies—a process that is often low-throughput, resource-intensive, and a significant hurdle to progress. Twist's platform is designed to provide robust expression of antibody candidates with yields generated for potential antibody hits against a specific antigen. Learn about the expression data Twist will provide you in this flyer.